ArticleJournal of clinical practice and research2025
Are Nesfatin-1, Apelin, Chemerin, Omentin-1, and Resistin Hormone Levels Comparable in Individuals with Opioid Use Disorder and Obesity?
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The primary aim of this research was to assess whether individuals with obesity or opioid use disorder (OUD) exhibit altered levels of specific adipokines compared with healthy subjects. Materials and Methods: A total of 90 participants were included (obesity group: 30, OUD group: 30, control group: 30). Results: Participants in both the obesity and OUD groups exhibited significantly increased concentrations of resistin, chemerin, and omentin-1 (p<0.05). Conversely, apelin levels were substantially reduced in both groups compared to healthy controls (p=0.001). Notably, nesfatin-1 levels were significantly lower only in the OUD group relative to controls (p=0.005). No statistically significant difference in body mass index (BMI) was found between individuals with OUD and healthy subjects (p=0.619). Conclusion: These findings suggest that obesity may share pathophysiological similarities with addiction. Therefore, obesity management should include psychological support. Additionally, considering the physiological roles of adipokine-related hormones, patients should be closely monitored for blood glucose levels, insulin resistance, diabetes mellitus, lipolysis, inflammation, and clinical complications such as atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.